{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:00:47Z","timestamp":1788454847811,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100010659","name":"Erasmus Universitair Medisch Centrum Rotterdam","doi-asserted-by":"publisher","award":["Mrace Grant"],"award-info":[{"award-number":["Mrace Grant"]}],"id":[{"id":"10.13039\/501100010659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40262-025-01486-4","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T18:25:44Z","timestamp":1742322344000},"page":"585-598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Leveraging Clinical Data to Enhance the Performance Evaluation of Ceftriaxone Population Pharmacokinetic Models in Children"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1835-0749","authenticated-orcid":false,"given":"Stef","family":"Schouwenburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Preijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2158-6376","authenticated-orcid":false,"given":"Alan","family":"Abdulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5197-2656","authenticated-orcid":false,"given":"Enno D.","family":"Wildschut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1202-3643","authenticated-orcid":false,"given":"Birgit C. P.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1259-581X","authenticated-orcid":false,"given":"Matthijs","family":"de Hoog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"issue":"2","key":"1486_CR1","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1097\/PCC.0000000000002198","volume":"21","author":"SL Weiss","year":"2020","unstructured":"Weiss SL, Peters MJ, Alhazzani W, Agus MSD, Flori HR, Inwald DP, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Pediat Crit Care Med. 2020;21(2):e52\u2013106.","journal-title":"Pediat Crit Care Med."},{"issue":"Suppl 3","key":"1486_CR2","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/j.cmi.2016.01.007","volume":"22","author":"D van de Beek","year":"2016","unstructured":"van de Beek D, Cabellos C, Dzupova O, Esposito S, Klein M, Kloek AT, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016;22(Suppl 3):S37-62.","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"1486_CR3","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s40262-021-01035-9","volume":"60","author":"SJF Hartman","year":"2021","unstructured":"Hartman SJF, Upadhyay PJ, Hagedoorn NN, Math\u00f4t RAA, Moll HA, van der Flier M, et al. current ceftriaxone dose recommendations are adequate for most critically ill children: results of a population pharmacokinetic modeling and simulation study. Clin Pharmacokinet. 2021;60(10):1361\u201372.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1486_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.2042-7158.2010.01179.x","volume":"63","author":"S Iida","year":"2010","unstructured":"Iida S, Kawanishi T, Hayashi M. Indications for a ceftriaxone dosing regimen in Japanese paediatric patients using population pharmacokinetic\/pharmacodynamic analysis and simulation. J Pharm Pharmacol. 2010;63(1):65\u201372.","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"1486_CR5","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01427-21","volume":"66","author":"S Tang Girdwood","year":"2022","unstructured":"Tang Girdwood S, Dong M, Tang P, Stoneman E, Jones R, Yunger T, et al. Population pharmacokinetic modeling of total and free ceftriaxone in critically ill children and young adults and Monte Carlo simulations support twice daily dosing for target attainment. Antimicrob Agents Chemother. 2022;66(1): e0142721.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1486_CR6","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1128\/AAC.01412-20","volume":"64","author":"YK Wang","year":"2020","unstructured":"Wang et al. Optimal dosing of ceftriaxone in infants based on a developmental population pharmacokinetic-pharmacodynamic analysis. Antimicrob Agents Chemother. 2020;64(11):1547\u201356.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1486_CR7","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00228-020-02939-4","volume":"76","author":"MW Khan","year":"2020","unstructured":"Khan MW, Wang YK, Wu YE, Tang BH, Kan M, Shi HY, et al. Population pharmacokinetics and dose optimization of ceftriaxone for children with community-acquired pneumonia. Eur J Clin Pharmacol. 2020;76(11):1547\u201356.","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"1486_CR8","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3109\/00498258709167406","volume":"17","author":"AC Popick","year":"1987","unstructured":"Popick AC, Crouthamel WG, Bekersky I. Plasma protein binding of ceftriaxone. Xenobiotica. 1987;17(10):1139\u201345.","journal-title":"Xenobiotica"},{"issue":"2","key":"1486_CR9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1128\/AAC.21.2.248","volume":"21","author":"UB Schaad","year":"1982","unstructured":"Schaad UB, Stoeckel K. Single-dose pharmacokinetics of ceftriaxone in infants and young children. Antimicrob Agents Chemother. 1982;21(2):248\u201353.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"1486_CR10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/phar.2774","volume":"43","author":"S Tang Girdwood","year":"2023","unstructured":"Tang Girdwood S, Tang P, Fenchel M, Dong M, Stoneman E, Jones R, et al. Pharmacokinetic parameters over time during sepsis and the association of target attainment and outcomes in critically ill children and young adults receiving ceftriaxone. Pharmacotherapy. 2023;43(7):609\u201321.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"1486_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00467-018-4120-2","volume":"35","author":"E Dhont","year":"2020","unstructured":"Dhont E, Van Der Heggen T, De Jaeger A, Vande Walle J, De Paepe P, De Cock PA. Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients? Pediatr Nephrol. 2020;35(1):25\u201339.","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"1486_CR12","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/jac\/dkad046","volume":"78","author":"TMJ Ewoldt","year":"2023","unstructured":"Ewoldt TMJ, Bahmany S, Abdulla A, Muller AE, Endeman H, Koch BCP. Plasma protein binding of ceftriaxone in critically ill patients: can we predict unbound fractions? J Antimicrob Chemother. 2023;78(4):1059\u201365.","journal-title":"J Antimicrob Chemother"},{"key":"1486_CR13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00779-20","author":"M Kan","year":"2020","unstructured":"Kan M, Shi HY, Han B, Wu YE, Li Q, Guo ZX, et al. Prediction of unbound ceftriaxone concentration in children: simple bioanalysis method and basic mathematical equation. Antimicrob Agents Chemother. 2020. https:\/\/doi.org\/10.1128\/AAC.00779-20.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1486_CR14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/bcp.12636","volume":"80","author":"M Schleibinger","year":"2015","unstructured":"Schleibinger M, Steinbach CL, T\u00f6pper C, Kratzer A, Liebchen U, Kees F, et al. Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients. Br J Clin Pharmacol. 2015;80(3):525\u201333.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1486_CR15","doi-asserted-by":"publisher","first-page":"540","DOI":"10.3390\/antibiotics10050540","volume":"10","author":"C Lacroix","year":"2021","unstructured":"Lacroix C, Bera-Jonville AP, Montastruc F, Velly L, Micallef J, Guilhaumou R. Serious neurological adverse events of ceftriaxone. Antibiotics (Basel). 2021;10(5):540.","journal-title":"Antibiotics (Basel)."},{"key":"1486_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.750080","volume":"12","author":"S Schouwenburg","year":"2021","unstructured":"Schouwenburg S, Wildschut ED, de Hoog M, Koch BCP, Abdulla A. The pharmacokinetics of beta-lactam antibiotics using scavenged samples in pediatric intensive care patients: the EXPAT Kids study protocol. Front Pharmacol. 2021;12: 750080.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1486_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Mu\u00f1oz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629\u201337.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"1486_CR18","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/s00467-010-1533-y","volume":"25","author":"DP Boer","year":"2010","unstructured":"Boer DP, de Rijke YB, Hop WC, Cransberg K, Dorresteijn EM. Reference values for serum creatinine in children younger than 1 year of age. Pediatr Nephrol. 2010;25(10):2107\u201313.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"1486_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/bcp.13431","volume":"84","author":"JJ Mao","year":"2018","unstructured":"Mao JJ, Jiao Z, Yun HY, Zhao CY, Chen HC, Qiu XY, Zhong MK. External evaluation of population pharmacokinetic models for ciclosporin in adult renal transplant recipients. Br J Clin Pharmacol. 2018;84(1):153\u201371.","journal-title":"Br J Clin Pharmacol"},{"key":"1486_CR20","doi-asserted-by":"crossref","unstructured":"McCann S, Helfer VE, Balevic SJ, Hornik CD, Goldstein SL, Autmizguine J, et al. Using real-world data to externally evaluate population pharmacokinetic models of dexmedetomidine in children and infants. J Clin Pharmacol. 2024;64(8):963-974.","DOI":"10.1002\/jcph.2434"},{"issue":"4","key":"1486_CR21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40262-023-01233-7","volume":"62","author":"M El Hassani","year":"2023","unstructured":"El Hassani M, Marsot A. External evaluation of population pharmacokinetic models for precision dosing: current state and knowledge gaps. Clin Pharmacokinet. 2023;62(4):533\u201340.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1486_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/cpt.2065","volume":"109","author":"DW Uster","year":"2021","unstructured":"Uster DW, Stocker SL, Carland JE, Brett J, Marriott DJE, Day RO, Wicha SG. A model averaging\/selection approach improves the predictive performance of model-informed precision dosing: vancomycin as a case study. Clin Pharmacol Ther. 2021;109(1):175\u201383.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1486_CR23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10928-021-09793-6","volume":"49","author":"E Sibieude","year":"2022","unstructured":"Sibieude E, Khandelwal A, Girard P, Hesthaven JS, Terranova N. Population pharmacokinetic model selection assisted by machine learning. J Pharmacokinet Pharmacodyn. 2022;49(2):257\u201370.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1486_CR24","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/s40262-024-01425-9","volume":"63","author":"BC Agema","year":"2024","unstructured":"Agema BC, Kocher T, \u00d6zt\u00fcrk AB, Giraud EL, van Erp NP, de Winter BCM, et al. Selecting the best pharmacokinetic models for a priori model-informed precision dosing with model ensembling. Clin Pharmacokinet. 2024;63:1449\u201361.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1486_CR25","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.3390\/pharmaceutics14071426","volume":"14","author":"A Duong","year":"2022","unstructured":"Duong A, Simard C, Williamson D, Marsot A. Model re-estimation: an alternative for poor predictive performance during external evaluations? Example of gentamicin in critically ill patients. Pharmaceutics. 2022;14(7):1426.","journal-title":"Pharmaceutics"},{"key":"1486_CR26","unstructured":"EUCAST. Clinical breakpoints and dosing of antibiotics: EUCAST. 2021. http:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed October, 2024."},{"key":"1486_CR27","unstructured":"Pr\u00e1sil P, Buchta V, Paterov\u00e1 P, Hanovcov\u00e1 I. (Penetration of ceftriaxone into the cerebrospinal fluid and its relationship to inflammatory markers during bacterial meningitis) Pr\u016fnik ceftriaxonu do likvoru a jeho v vztah k marker\u016fm z\u00e1netu v pr\u016fbehu invazivn\u00ed bakteri\u00e1ln\u00ed infekce. Klin Mikrobiol Infekc Lek. 2010;16(2):64\u201372."},{"issue":"4","key":"1486_CR28","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1093\/jac\/dky553","volume":"74","author":"P Le Turnier","year":"2019","unstructured":"Le Turnier P, Navas D, Garot D, Guimard T, Bernard L, Tattevin P, et al. Tolerability of high-dose ceftriaxone in CNS infections: a prospective multicentre cohort study. J Antimicrob Chemother. 2019;74(4):1078\u201385.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1486_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000534890","volume":"6","author":"M Sylva","year":"2023","unstructured":"Sylva M, Abdulla A, Koch BCP, Mulder J. Cephalosporin-related neurotoxicity in a ceftriaxone-treated critically ill child: a case report. Case Rep Acute Med. 2023;6(1):19\u201324.","journal-title":"Case Rep Acute Med."},{"issue":"9","key":"1486_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103715","volume":"28","author":"J Denck","year":"2023","unstructured":"Denck J, Ozkirimli E, Wang K. Machine-learning-based adverse drug event prediction from observational health data: a review. Drug Discov Today. 2023;28(9): 103715.","journal-title":"Drug Discov Today"},{"key":"1486_CR31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3389\/fphar.2020.00172","volume":"11","author":"D Alihodzic","year":"2020","unstructured":"Alihodzic D, Broeker A, Baehr M, Kluge S, Langebrake C, Wicha SG. Impact of inaccurate documentation of sampling and infusion time in model-informed precision dosing. Front Pharmacol. 2020;11:172.","journal-title":"Front Pharmacol"},{"issue":"10","key":"1486_CR32","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1111\/bcp.14803","volume":"87","author":"S Ryu","year":"2021","unstructured":"Ryu S, Jung WJ, Jiao Z, Chae JW, Yun HY. External evaluation of the predictive performance of seven population pharmacokinetic models for phenobarbital in neonates. Br J Clin Pharmacol. 2021;87(10):3878\u201389.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1486_CR33","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s13318-024-00897-1","volume":"49","author":"M El Hassani","year":"2024","unstructured":"El Hassani M, Liebchen U, Marsot A. Does sample size, sampling strategy, or handling of concentrations below the lower limit of quantification matter when externally evaluating population pharmacokinetic models? Eur J Drug Metab Pharmacokinet. 2024;49(4):419\u201336.","journal-title":"Eur J Drug Metab Pharmacokinet"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01486-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01486-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01486-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T15:21:42Z","timestamp":1745940102000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01486-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1486"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01486-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"27 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the MRace grant of the Erasmus University Medical Centre, Rotterdam, The Netherlands.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Birgit C.P. Koch is an Editorial Board member of Clinical Pharmacokinetics. Birgit C.P. Koch was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Stef Schouwenburg, Tim Preijers, Alan Abdulla , Enno D. Wildschut, and Matthijs de Hoog have no conflicts of interest to declare concerning this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The EXPAT Kids study was approved by the Erasmus MC Medical Ethical Committee (NL76194.078.21) (NL9326).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written, informed consent was obtained from all participants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data and material are accessible upon reasonable request by contacting the corresponding author..","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The model codes that support the findings of this study are accessible upon reasonable request by contacting the corresponding author.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}